Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study [0.03%]
HER2阳性乳腺癌继发脑转移患者的现实世界预后：一项基于澳大利亚多中心登记的队列研究
Iris Tung,Cristina Moldovan,Vanessa Wong et al.
Iris Tung et al.
Background: The development of brain metastases occurs commonly in HER2-positive metastatic breast cancer and is associated with a poorer prognosis. The advent of HER2-targeted therapy has improved overall survival, but t...
Genetic Variations in IFNGR1, BDNF and IL-10 May Predict the Susceptibility to Depression and Anxiety in Chinese Women With Breast Cancer [0.03%]
IFNGR1、BDNF和IL-10基因多态性与中国人乳腺癌女性患者抑郁和焦虑的易感性的关联分析
Bo Lan,Dan Lv,Xiaoying Sun et al.
Bo Lan et al.
Background: A large number of breast cancer survivors suffer from psychological distress. The purpose of this study was to investigate the association between genetic variations in Chinese breast cancer patients and anxie...
Observational Study
Clinical breast cancer. 2022 Oct;22(7):674-680. DOI:10.1016/j.clbc.2022.07.002 2022
Characterizing Clinicopathologic Features of Estrogen Receptor-Positive/Progesterone Receptor-Negative Breast Cancers [0.03%]
雌激素受体阳性/黄体酮受体阴性乳腺癌的临床病理特征分析
Fei Fei,Gene P Siegal,Shi Wei
Fei Fei
Background: While most estrogen receptor-positive (ER+) breast cancers express progesterone receptor (PR), a small subset of tumors exhibits an ER+/PR- phenotype despite the fact that PR is an ER-dependent gene product. P...
Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis [0.03%]
新辅助化疗时代乳腺癌局部区域复发和生存的.population.基于研究分析
Sonja Murchison,Alan Nichol,Caroline Speers et al.
Sonja Murchison et al.
Background: Data guiding radiotherapy (RT) decisions after neoadjuvant chemotherapy (NAC) is largely retrospective, based on older treatment approaches without molecular subtype information. This study evaluated outcomes ...
Neil Chevli,Kaidi Wang,Waqar Haque et al.
Neil Chevli et al.
Purpose: Pure Mucinous breast carcinoma (PMBC) is an invasive breast cancer with favorable prognosis. While pathology-specific guidelines exist for PMBC regarding adjuvant chemotherapy and endocrine therapy, no recommenda...
Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives [0.03%]
激素受体阳性乳腺癌的免疫检查点阻断：耐药机制及未来展望
Ioannis A Vathiotis,Ioannis Trontzas,Niki Gavrielatou et al.
Ioannis A Vathiotis et al.
Anti-programmed cell death protein 1 immunotherapy has been incorporated in the treatment algorithm of triple-negative breast cancer (TNBC). However, clinical trial results for patients with hormone receptor (HR)-positive disease appear les...
Rehabilitation for Women Undergoing Breast Cancer Surgery: A Systematic Review and Meta-Analysis of the Effectiveness of Early, Unrestricted Exercise Programs on Upper Limb Function [0.03%]
乳腺癌术后女性的康复：早期无限制运动项目对上肢功能的影响的系统评价和网络 meta 分析
Tara Redemski,Daniel G Hamilton,Samuel Schuler et al.
Tara Redemski et al.
Upper limb impairments are common in women following surgery for breast cancer. Range of movement (ROM) exercises are commonly prescribed, but the optimal timing to begin these exercises is not clear. The aim of this systematic review and m...
Mode of Detection of Second Events in Routine Surveillance of Early Stage Breast Cancer Patients [0.03%]
早期乳腺癌患者常规监测中第二事件的检测方式
Soe Min Tun,Sunitha Alluri,Vida Rastegar et al.
Soe Min Tun et al.
Introduction: NCCN and ASCO guidelines recommend breast cancer (BC) follow-up to include clinical breast examination (CBE) every 6 months and annual mammography (AM) for 5 years. Given limited data to support CBE, we eval...
Development and Validation a Survival Prediction Model and a Risk Stratification for Elderly Locally Advanced Breast Cancer [0.03%]
老年局部晚期乳腺癌预后预测模型及风险分层模型的建立和验证
Xiangdi Meng,Xiaolong Chang,Xiaoxiao Wang et al.
Xiangdi Meng et al.
Purpose: we aimed to develop an individualized survival prediction model for elderly locally advanced breast cancer (LABC) and stratify its risk to assist in the treatment and follow-up of patients. ...
Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-Resistance [0.03%]
伊瑞替康治疗后使用紫杉类药物治疗晚期乳腺癌的交叉耐药性现象分析
Alicia F C Okines,Tazia Irfan,Kabir Mohammed et al.
Alicia F C Okines et al.
Introduction: The tubulin inhibitor, eribulin, improves survival for previously treated advanced breast cancer (ABC) compared to chemotherapy of physician's choice, including vinorelbine, an older anti-tubulin. Vinorelbin...